

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Daniel G. Chain Art Unit : 1649
Serial No. : 10/084,380 Examiner : Gregory S. Emch
Filed : February 28, 2002 Conf. No. : 3496
Title : **SPECIFIC ANTIBODIES TO AMYLOID BETA PEPTIDE,
PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE
THEREOF**

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

DECLARATION OF NORMAN R. RELKIN, M.D., PH.D., UNDER 37 C.F.R. 1.132

Norman R. Relkin declares and states as follows:

1. I am a citizen of the United States and am more than twenty-one years of age.

2. I am an associate professor of Clinical Neurology and Neuroscience at Weill Cornell Medical College. I obtained a doctoral degree (Ph.D.) in Neuroscience as well as a medical doctorate (M.D.) in 1987. I joined the Cornell Medical College faculty in 1991. I am the founding director of the Weill Cornell Memory Disorders Program. I became Board Certified in Neurology in 1992. I am a practicing physician in the Memory Disorders subspecialty of Neurology and have recognized expertise relating to Alzheimer's disease (AD). I also am also the head of a research laboratory at Weill Cornell that carries out basic and translational studies relating to AD immunotherapy.

3. I have conducted research in the field of AD since 1993. Specifically, I have studied methods of improving prediction, diagnosis and treatment of AD and other forms of dementia. I am a co-inventor of U.S. patent application no. 11/910,721, published as US 20090075395 A1, and entitled, "Multiplexed Biomarkers for Monitoring the Alzheimer's Disease State of a Subject." I have participated in, designed and/or led more than a dozen AD clinical trials, including Phase 1 and 2 trials of Intravenous Immunoglobulin (IGIV) for treatment of mild to moderate AD. I designed and currently lead the NIH/Baxter co-sponsored Phase 3 pivotal study of IGIV for the treatment of mild to moderate AD being carried out at 41 sites in